L-N-ethylleucine | 64991-33-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-N-ethylleucine
• 英文别名: N-ethyl-L-leucine；N-Aethyl-L-leucin；L-α-Aethyl-isocapronsaeure；N-ethyl-leucine；(2S)-2-(ethylamino)-4-methylpentanoic acid
• CAS: 64991-33-9
• 化学式: C₈H₁₇NO₂
• 分子量: 159.228
• InChiKey: OLTRFLJKPXPCCI-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (4S)-3-(chloromethyl)-4-(2-methylpropyl)-2,2-bis(trifluoromethyl)-1,3-oxazolidin-5-one 在 盐酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醚 为溶剂， 反应 169.33h， 生成 L-N-ethylleucine
  参考文献：
  名称：

  Synthesis of α-N-Ethylamino Acids and their Derivatives

  摘要：

  A new synthesis of alpha-N-ethylamino acids starting from alpha-amino acids using hexafluoroacetone as protecting and activating agent is described. The hexafluoroacetone-protected N-ethylamino acid derivatives obtained are activated lactons. Therefore, they can be directly transformed without the need of an additional activation step with various nucleophiles into the corresponding carboxylic acid derivatives.

  DOI：

  10.1007/s007060070057

文献信息

• [EN] SUBSTITUTED PEPTIDYLAMINE CALCIUM CHANNEL BLOCKERS<br/>[FR] INHIBITEURS DES CANAUX DE CALCIUM DE PEPTIDYLAMINE SUBSTITUEE
  申请人：WARNER-LAMBERT COMPANY

  公开号：WO1998054123A1

  公开（公告）日：1998-12-03

  (EN) The present invention provides compounds that block calcium channels having Formula (I). The present invention also provides methods of using the compounds of Formula (I) to treat stroke, cerebral ischemia, head trauma, or epilepsy and to pharmaceutical compositions that contain the compounds of Formula (I).(FR) L'invention concerne des composés inhibiteurs des canaux de calcium et représentés par la formule (I). Elle concerne également des procédés servant à mettre en application ces composés afin de traiter les attaques, l'ischémie cérébrale, le traumatisme crânien ou l'épilepsie, ainsi que des compositions pharmaceutiques contenant ces composés.

  (中) 本发明提供了具有公式（I）的阻断钙通道的化合物。本发明还提供了使用公式（I）的化合物治疗中风、脑缺血、头部创伤或癫痫的方法，以及含有公式（I）的制药组合物。
• Urea derivative, process for producing the same, and use
  申请人：Kubo Keiji

  公开号：US20070093501A1

  公开（公告）日：2007-04-26

  The present invention provides a urea derivative or a salt thereof, which is useful as a therapeutic agent for thrombosis. The derivative is represented by Formula (I): wherein Cy is an aromatic hydrocarbon group which may be substituted or an aromatic heterocyclic group which may be substituted; R 1 is a hydrogen atom or a hydrocarbon group which may be substituted; V is —C(O)—, —S(O)—, or —S(O) 2 —; W is —N(R 2 )—, —O—, or a bond (wherein R 2 is a hydrogen atom or a hydrocarbon group which may be substituted); X is alkylene which may be substituted; Y is —C(O)—, —S(O)—, or —S(O) 2 —; Z is a bond, a chain hydrocarbon group which may be substituted, or —N═; ring A is a non-aromatic nitrogen-containing heterocyclic ring which may be substituted; ring B is a nitrogen-containing heterocyclic ring which may be substituted; and [Chemical formula 2] , are each independently a single bond or a double bond; provided that R 1 may be bonded to R 2 to form a non-aromatic nitrogen-containing heterocyclic ring and that R 2 may be bonded to a substituent of X to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted.

  本发明提供一种尿素衍生物或其盐，其作为治疗血栓症的治疗剂是有用的。该衍生物由公式（I）表示：其中，Cy是芳香族羟基烃基或芳香族杂环基，可以被取代；R1是氢原子或可以被取代的碳氢基团；V是-C（O）-，-S（O）-或-S（O）2-；W是-N（R2）-，-O-或键（其中R2是氢原子或可以被取代的碳氢基团）；X是可以被取代的烷基；Y是-C（O）-，-S（O）-或-S（O）2-；Z是键，可以被取代的链烃基团或-N═；环A是非芳香族含氮杂环环，可以被取代；环B是含氮杂环环，可以被取代；而[化学式2]都是单键或双键；但是，R1可以与R2连接形成非芳香族含氮杂环环，而R2可以与X的取代基连接形成可以被取代的非芳香族含氮杂环环。
• Derivatives of 18Beta-Glycyrrhetinic Acid
  申请人：Ward Simon

  公开号：US20090076032A1

  公开（公告）日：2009-03-19

  The present invention relates to novel derivatives of 18β-glycyrrhetinic acid and methods of synthesising the derivatives. Also included within the scope of the present invention are pharmaceutical compositions comprising the derivatives of the present invention and medical uses of the derivatives, including their use in inhibiting enzymes such as retinol dehydrogenases. The present invention also relates to methods of treating diseases, such as hyperproliferative diseases, neoplasms, cancers and photoageing.

  本发明涉及18β-甘草酸的新衍生物及其合成方法。本发明的范围还包括包含本发明衍生物的制药组合物以及本发明衍生物的医学用途，包括它们在抑制酶如视黄醇脱氢酶中的使用。本发明还涉及治疗疾病的方法，例如增生性疾病、肿瘤、癌症和光老化。
• Malodors reduction
  申请人：QUEST INTERNATIONAL B.V.

  公开号：EP0392619A2

  公开（公告）日：1990-10-17

  The invention concerns a method of reducing the organoleptic effect of undesirable aldehydic components in a triglyceride or derivative thereof by addition of a reaction product of an amine and an organoleptically acceptable aldehyde. The triglyceride may be a food or food component such as an edible fat or a surface active agent such as a detergent. The reaction product may be incorporated in the perfume or flavour to be added to the triglyceride or derivative thereof without distorting their organoleptic effect.

  本发明涉及一种通过添加胺和有机感官上可接受的醛的反应产物来降低甘油三酯或其衍生物中不受欢迎的醛成分的感官效果的方法。甘油三酯可以是食品或食品成分，如食用脂肪或表面活性剂，如洗涤剂。反应产物可与香水或香精结合，添加到甘油三酯或其衍生物中，而不会改变其感官效果。
• Cyclic peptides and use thereof
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0528312A2

  公开（公告）日：1993-02-24

  Disclosed are (1) a cyclic hexapeptide represented by formula [I] or a salt thereof: wherein X and Y each represent a-amino acid residues, A represents a D-acidic-a-amino acid residue, B represents a neutral-a-amino acid residue, C represents an L-a-amino acid residue and D represents a D-a-amino acid residue having an aromatic ring group; and (2) a pharmaceutical composition comprising the peptide represented by formula [I] or a pharmaceutically acceptable salt thereof as an active ingredient.

  公开了 (1) 由式 [I] 表示的环六肽或其盐： 其中 X 和 Y 分别代表 a-氨基酸残基，A 代表 D-酸性-a-氨基酸残基，B 代表中性-a-氨基酸残基，C 代表 L-a-氨基酸残基，D 代表具有芳香环基的 D-a-氨基酸残基；以及 (2) 一种药物组合物，其活性成分包含式 [I] 所代表的肽或其药学上可接受的盐。